T cell engaging bispecific antibodies (TCBs) have recently become significant in cancer treatment. In this study we developed MSLN490, a novel TCB designed to target mesothelin (MSLN), a glycosylphosphatidylinositol (GPI)-linked glycoprotein highly expressed in various cancers, and evaluated its ...
(FL) and ≥2 prior therapies, and glofitamab (Glofit), approved for treatment of pts with R/R diffuse large B-cell lymphoma, or large B-cell lymphoma arising from FL, and ≥2 prior therapies, are CD20xCD3 T-cell engaging bispecific antibodies that redirect T cells to eliminate B cells...
using T-cell-engaging bispecific antibodies (TCBs) as a model therapy. We demonstrate that organoid–immune cell co-cultures are able to capture clinical toxicities overlooked by animal models and shed light on the cellular mechanisms that underpin these effects. Combined...
[2]Pillarisetti K, Powers G, Luistro L, et al.Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549. doi: 10.1182/bloodadvances.2020002393. [3]Smith, E., Olson, K., Haber, L. e...
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today? 2025, Presse Medicale Show abstract International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma:...
We previously described T cell engaging bispecific antibodies (T-BsAbs) using sequences of anti-CD3 (huOKT3) and anti-disialoganglioside [GD2] (hu3F8) or anti-epidermal growth factor receptor-2 [HER2] (trastuzumab) antibody structured on IgG-[L]-scFv format with silenced Fc, exerting ...
Patty A.Culp,Jeremiah D.Degenhardt,Danielle E.Dettling,ChadMay Volume 1 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy Chapter Nine - T-cell engaging bispecific antibody therapy网页链接 Ganesan, R., Chennupati, V., Ramachandran, B. et al. Selective recruitment of γδ...
1.Thieblemont C, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 ...
A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer. Clin. Cancer Res. 26, 5258–5268 (2020). Services Explore a career with us Partnering interests in Oncology Print this Article Tags Immuno-oncology Cancer T-...
A bi-specific antibody that binds both T cells and a tumor-specific intracellular antigen shows therapeutic promise in mouse models of cancer. Intracellular tumor antigens presented on the cell surface in the context of human leukocyte antigen (HLA) mole